ABCA1 and neoplasm: Furthermore, the existing body of research pertaining to the therapeutic targeting of ABCA1 in tumor treatment is limited, with a dearth of pertinent clinical trials that substantiate the potential benefits of ABCA1 targeting, specifically in terms of progression-free survival and OS.